Prime Highlights-
- European Commission approves a new four-week dosing schedule for pegunigalsidase alfa.
- The revised schedule reduces hospital visits, easing treatment for adults with Fabry disease.
Key Facts-
- Fabry disease is a rare genetic disorder affecting multiple organs, including the heart and kidneys.
- Studies confirm that the four-week dosing is safe, effective, and maintains therapy benefits.
Background-
The European Commission approved a new dosing schedule for pegunigalsidase alfa, a treatment for adults with Fabry disease. Patients can now take the therapy once every four weeks instead of every two weeks.
The new schedule makes treatment easier. Patients need fewer visits to hospitals or clinics, which helps them manage their daily routines with less disruption.
Fabry disease is a rare inherited condition that can affect several organs, including the heart and kidneys. Enzyme replacement therapy lowers the buildup of harmful substances in the body and slows the disease.
The revised dosing follows studies showing that taking the treatment every four weeks is safe and effective. Regulators say the new schedule maintains the therapy’s benefits while offering more convenience.
Healthcare providers across the European Union can now offer this option to eligible adults. Patient groups and doctors have welcomed the approval, calling it an important step in improving care for those living with this rare condition.
Chiesi Global Rare Diseases and Protalix BioTherapeutics, the companies behind Elfabrio, said they are committed to supporting patients and ensuring smooth access to the new dosing option.
This approval highlights Europe’s focus on improving rare disease care. It also shows how small changes in treatment schedules can make a big difference for patients and families.
